Evidence map›Paper›PMID 38584055›Full record

ArticleVaccine2024

Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.

Anna N Chard, Chiedza Machingaidze, Sergio Loayza, Radhika Gharpure, Francisco Nogareda, Rosalba González, Rhina Domínguez, Yeny O Tinoco, Fatimah S Dawood, Joseph Daniel Carreon and 7 more

Abstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anna N ChardInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States. Electronic address: mmn9@cdc.gov.
Chiedza MachingaidzeGlobal Influenza Programme, World Health Organization, Av. Appia 20, 1202 Geneva, Switzerland.
Sergio LoayzaPan American Health Organization, 525 23rd St NW, Washington, DC 20037, United States.
Radhika GharpureInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States.
Francisco NogaredaPan American Health Organization, 525 23rd St NW, Washington, DC 20037, United States.
Rosalba GonzálezGorgas Memorial Institute of Health Studies, Ave. Justo Arosemena, Calle 35, Panama City, Panama.
Rhina DomínguezNational Institute of Health of El Salvador, C. Gabriela Mistral 211, San Salvador, El Salvador.
Yeny O TinocoU.S. Naval Medical Research Unit SOUTH, Av. Venezuela. Cuadra 36 s/n. Bellavista. Callao, Lima, Peru.
Fatimah S DawoodInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States.
Joseph Daniel CarreonInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States.
Kathryn E LafondInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States.
Jorge JaraPan American Health Organization, 525 23rd St NW, Washington, DC 20037, United States.
Eduardo Azziz-BaumgartnerInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States.
Vanessa CozzaGlobal Influenza Programme, World Health Organization, Av. Appia 20, 1202 Geneva, Switzerland.
Paula CoutoPan American Health Organization, 525 23rd St NW, Washington, DC 20037, United States.
Melissa A RolfesInfluenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, United States; Global Influenza Programme, World Health Organization, Av. Appia 20, 1202 Geneva, Switzerland.
Stefano TempiaGlobal Influenza Programme, World Health Organization, Av. Appia 20, 1202 Geneva, Switzerland.

Funding

The purpose of this cooperative agreement is to enable public health departments to bill healthH23IP000940 · IP · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI SWANSON, ROBERT · 2014 to 2014
$500k
Intramural CDC HHS CC999999NCIRD CDC HHS NU51IP000940World Health Organization 001
6 · The paper itself

Abstract

backgroundEstimating the burden of disease averted by vaccination can assist policymakers to implement, adjust, and communicate the value of vaccination programs. Demonstrating the use of a newly available modeling tool, we estimated the burden of influenza illnesses averted by seasonal influenza vaccination in El Salvador, Panama, and Peru during 2011-2018 among two influenza vaccine target populations: children aged 6-23 months and pregnant women.

methodsWe derived model inputs, including incidence, vaccine coverage, vaccine effectiveness, and multipliers from publicly available country-level influenza surveillance data and cohort studies. We also estimated changes in illnesses averted when countries' vaccine coverage was achieved using four different vaccine deployment strategies.

resultsAmong children aged 6-23 months, influenza vaccination averted an estimated cumulative 2,161 hospitalizations, 81,907 medically-attended illnesses, and 126,987 overall illnesses during the study period, with a prevented fraction ranging from 0.3 % to 12.5 %. Among pregnant women, influenza vaccination averted an estimated cumulative 173 hospitalizations, 6,122 medically attended illnesses, and 16,412 overall illnesses, with a prevented fraction ranging from 0.2 % to 10.9 %. Compared to an influenza vaccine campaign with equal vaccine distribution during March-June, scenarios in which total cumulative coverage was achieved in March and April consistently resulted in the greatest increase in averted illness (23 %-3,129 % increase among young children and 22 %-3,260 % increase among pregnant women). DISCUSSION: Influenza vaccination campaigns in El Salvador, Panama, and Peru conducted between 2011 and 2018 prevented hundreds to thousands of influenza-associated hospitalizations and illnesses in young children and pregnant women. Existing vaccination programs could prevent additional illnesses, using the same number of vaccines, by achieving the highest possible coverage within the first two months of an influenza vaccine campaign.

Indexed as

Influenza, HumanInfluenza VaccinesVaccinationAdultEl SalvadorFemaleHospitalizationHumansImmunization ProgramsIncidenceInfantMalePanamaPeruPregnancyPregnant PeopleInfluenza VaccinesAverted illnessCompartment modelInfluenza epidemiologyInfluenza vaccineVaccine effectiveness

Identifiers

PMID38584055
PMCPMC11455982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.